Atossa Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Atossa Therapeutics reports progress in its (Z)-endoxifen clinical trials for breast cancer and rare diseases, alongside continued operating losses and a recent reverse stock split.
NASDAQ
Atossa Therapeutics' 2024 10-K filing reveals a strategic shift towards a metastatic breast cancer indication for (Z)-endoxifen, alongside ongoing Phase 2 trials and financial updates.
NASDAQ
Atossa Therapeutics' 2023 annual report highlights ongoing clinical trials for (Z)-endoxifen and strategic investments in other healthcare opportunities, while acknowledging the need for future capital raises.